In the Specification:

Please amend the specification as shown:

Please delete the paragraph on page 14, lines 4-12 and replace it with the following paragraph:

Immunogens displaying the epitope necessary to produce antibodies of the present invention may be prepared as oligomeric intermediate mimics comprising amyloid peptides or proteins. For example, A peptides, such as A 40 and A 41, -synuclein, IAPP(C2AandC7A) where alanine is substituted for the naturally occurring cysteine in IAPP, Polyglutamine KKQ40KK (SEQ ID NO: 5) or poly glutamine where the number of Q residues is greater than 32, Calcitonin, TTR and its mutants TTR Pro⁵⁵, TTR Phe⁷⁸, vitronictin, poly Lysine, poly arginine, serum amyloid A, cystantin C, IgG kappa light chain, other amyloid peptides disclosed herein and amyloid peptides associated each amyloid disease disclosed herein may be used.

Please delete the paragraph on page 20, line 22 to page 21, line 4 and replace it with the following paragraph:

In addition, oligomeric intermediates formed from variants and fragments of wild type A 42, A 40 including, without limitation A 42 (A21G) Flemish mutation), A 42 (E22Q) Dutch mutation, A 42 (E22G) Arctic mutation, A 42 (D23N) Iowa mutation, A 40 (A21G) Flemish mutation), A 40 (E22Q) Dutch mutation, A 40 (E22Q) Arctic mutation, A 40 (D23N) Iowa mutation, A 40 (E22Q &D23N) Dutch & Iowa mutations, A 3-42 (pGlu 3), A 3-40 (pGlu 3), A 8-42, A 17-42, A 1-16, A 3-11, A 25-35, A 4-16 (3 analogues, Cys¹⁶ A 4-16, Ala⁴ A 4-16, and Ala¹⁰ A 4-16), His6 (SEQ ID NO: 10) A 40C40 (6 histidines appended to the amino terminus of AßC40) are recognized by the

antibodies of the present invention. Other oligomeric intermediates recognized by antibodies of the invention include, without limitation, oligomeric intermediates formed from IAPP(C2AandC7A) where alanine is substituted for the naturally occurring cysteine in IAPP, Polyglutamine KKQ40KK (SEQ ID NO: 5) or poly glutamine where the number of Q residues is greater than 32, Calcitonin, TTR and its mutants TTR Pro⁵⁵, TTR Phe⁷⁸, vitronictin, poly Lysine, poly arginine, serum amyloid A, cystantin C, IgG kappa light chain, oligomeric intermediates produced from other amyloid peptides disclosed herein and amyloid intermediates associated with amyloid diseases disclosed herein.

Please delete the paragraph on page 35, lines 4-5 and replace it with the following paragraph:

Human insulin, lysozyme, Polyglutamine KKQ40KK (SEQ ID NO: 5) and -synuclein were obtained from commercial or other sources.